{"title":"点评:Huang S.等。“阿尔茨海默病的生物流体生物标志物:进展、问题和观点。”神经科学通报(2022)","authors":"He Jin , Rong Wang","doi":"10.1016/j.urine.2022.07.001","DOIUrl":null,"url":null,"abstract":"<div><p>This paper by Huang S., et al. has retrospectively described the recent progress in biomarkers based on the A-T-N-X framework, A-T-N respectively represents Amyloid-Tau-Neurodegeneration, X represents biomarkers from central or peripheral related to the whole pathological course of Alzheimer's disease (AD). The framework of A-T-N-X is of great significance for understanding the whole spectrum of AD, but we still want to stress the importance of urine biomarkers for the early identification and effective management of AD.</p></div>","PeriodicalId":75287,"journal":{"name":"Urine (Amsterdam, Netherlands)","volume":"4 ","pages":"Pages 25-26"},"PeriodicalIF":0.0000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2590280622000067/pdfft?md5=54b2ac38e709f68a81aa588b4b8fc2dd&pid=1-s2.0-S2590280622000067-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Comments on: Huang S. et al. “Biofluid Biomarkers of Alzheimer's disease: Progress, problems, and perspectives.” Neuroscience Bulletin (2022)\",\"authors\":\"He Jin , Rong Wang\",\"doi\":\"10.1016/j.urine.2022.07.001\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>This paper by Huang S., et al. has retrospectively described the recent progress in biomarkers based on the A-T-N-X framework, A-T-N respectively represents Amyloid-Tau-Neurodegeneration, X represents biomarkers from central or peripheral related to the whole pathological course of Alzheimer's disease (AD). The framework of A-T-N-X is of great significance for understanding the whole spectrum of AD, but we still want to stress the importance of urine biomarkers for the early identification and effective management of AD.</p></div>\",\"PeriodicalId\":75287,\"journal\":{\"name\":\"Urine (Amsterdam, Netherlands)\",\"volume\":\"4 \",\"pages\":\"Pages 25-26\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2022-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2590280622000067/pdfft?md5=54b2ac38e709f68a81aa588b4b8fc2dd&pid=1-s2.0-S2590280622000067-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Urine (Amsterdam, Netherlands)\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590280622000067\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Urine (Amsterdam, Netherlands)","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590280622000067","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
Huang S.等人基于A-T-N-X框架回顾性描述了生物标志物的最新进展,A-T-N分别代表淀粉样蛋白- tau -神经变性,X代表与阿尔茨海默病(AD)整个病理过程相关的中枢或外周生物标志物。A-T-N-X的框架对于了解AD的全谱具有重要意义,但我们仍然要强调尿液生物标志物对于AD的早期识别和有效管理的重要性。
Comments on: Huang S. et al. “Biofluid Biomarkers of Alzheimer's disease: Progress, problems, and perspectives.” Neuroscience Bulletin (2022)
This paper by Huang S., et al. has retrospectively described the recent progress in biomarkers based on the A-T-N-X framework, A-T-N respectively represents Amyloid-Tau-Neurodegeneration, X represents biomarkers from central or peripheral related to the whole pathological course of Alzheimer's disease (AD). The framework of A-T-N-X is of great significance for understanding the whole spectrum of AD, but we still want to stress the importance of urine biomarkers for the early identification and effective management of AD.